Protective effects of octylseleno-xylofuranoside in a streptozotocin-induced mouse model of Alzheimer's disease.

Autor: Baldinotti R; Neurobiotechnology Research Group, Postgraduate Program in Biotechnology, Technologic Development Center, Federal University of Pelotas, Pelotas, RS, Brazil., Fronza MG; Neurobiotechnology Research Group, Postgraduate Program in Biotechnology, Technologic Development Center, Federal University of Pelotas, Pelotas, RS, Brazil., Fetter J; Neurobiotechnology Research Group, Postgraduate Program in Biotechnology, Technologic Development Center, Federal University of Pelotas, Pelotas, RS, Brazil., Silva L; Chemical Institute, Laboratory of Molecular Catalysis, Federal University of Rio Grande Do Sul, Porto Alegre, RS, Brazil., Bender CB; Technological Development Center, Division of Biotechnology, Molecular and Cellular Oncology Research Group and Cancer Biotechnology Laboratory, Federal University of Pelotas, Pelotas, RS, Brazil., Lüdtke DS; Chemical Institute, Laboratory of Molecular Catalysis, Federal University of Rio Grande Do Sul, Porto Alegre, RS, Brazil., Seixas FK; Technological Development Center, Division of Biotechnology, Molecular and Cellular Oncology Research Group and Cancer Biotechnology Laboratory, Federal University of Pelotas, Pelotas, RS, Brazil., Collares T; Technological Development Center, Division of Biotechnology, Molecular and Cellular Oncology Research Group and Cancer Biotechnology Laboratory, Federal University of Pelotas, Pelotas, RS, Brazil., Alves D; Center for Chemical, Pharmaceutical and Food Sciences, Laboratory of Clean Organic Synthesis, Federal University of Pelotas, Pelotas, RS, Brazil., Savegnago L; Neurobiotechnology Research Group, Postgraduate Program in Biotechnology, Technologic Development Center, Federal University of Pelotas, Pelotas, RS, Brazil. Electronic address: luciellisavegnago@yahoo.com.br.
Jazyk: angličtina
Zdroj: European journal of pharmacology [Eur J Pharmacol] 2021 Nov 05; Vol. 910, pp. 174499. Date of Electronic Publication: 2021 Sep 08.
DOI: 10.1016/j.ejphar.2021.174499
Abstrakt: Octylseleno-xylofuranoside (OSX) is an organic selenium compound which has previously shown antioxidant and antidepressant-like activities, trough the modulation of monoaminergic system and synaptic plasticity pathways. Since recent studies have suggested Major Depressive Disorder (MDD) as a potential risk factor or condition that precedes and correlates with Alzheimer's Disease (AD), this study aimed to evaluate the protective effects of OSX in an AD mouse model induced by intracerebroventricular injection of streptozotocin (STZ). To address this protective effect, mice were pre-treated with intragastrical OSX (0.1 mg/kg) or vehicle for 20 days. After the pre-treatment, mice were submitted to two alternated intracerebroventricular infusions of STZ (days 21 and 23) or saline. 15 days after the last STZ injection, cognitive and memory skills of the treated mice were evaluated on object recognition test, Y-maze, stepdown passive avoidance and social recognition paradigms. Added to that, measurements of oxidative stress markers and gene expression were evaluated in brain samples of the same mice groups. Mice pre-treatment with OSX protected mice from cognitive and memory decline elicited by STZ. This effect was attributed to the prevention of lipid peroxidation and modulation of acetylcholinesterase and monoamine oxidase activities in cerebral cortices and hippocampi by OSX treatment. Furthermore, OSX treatment demonstrated reduction of amyloidogenic pathway genes expression when compared to the control groups. Besides that, OSX treatment showed no hepatic and renal toxicity in the protocol used for treatment. Considering the antidepressant-like effect of OSX, together with the ability to prevent memory and cognitive impairment, this new compound may be an interesting strategy for targeting the comorbidity between MDD and AD, in a multitarget drug paradigm.
(Copyright © 2021. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: